Journal
SEMINARS IN CUTANEOUS MEDICINE AND SURGERY
Volume 36, Issue 3, Pages 124-130Publisher
FRONTLINE MEDICAL COMMUNICATIONS
DOI: 10.12788/j.sder.2017.0137
Keywords
-
Categories
Ask authors/readers for more resources
Crisaborole and dupilumab represent the first 2 Food and Drug Administration (FDA)-approved therapies for atopic dermatitis (AD) in more than 15 years, and there are many promising drugs currently in development. This new wave of therapeutics capitalizes on the large body of work clarifying the pathogenesis of AD over the last several decades. In particular, type 2 cytokine-driven inflammation and skin barrier dysfunction are key processes underlying AD pathogenesis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
